Tigecycline therapy in pediatric patients with multidrug resistant bacteremia.
Bacteremia
Bacteriemia
Children
Multidrug-resistant
Multirresistente
Niños
Tigeciclina
Tigecycline
Journal
Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
10
2019
revised:
09
12
2019
accepted:
09
12
2019
pubmed:
23
2
2020
medline:
25
8
2021
entrez:
22
2
2020
Statut:
ppublish
Résumé
Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients. In this study the effectiveness and safety of tigecycline in children was assessed retrospectively. A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2-32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse. Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria.
Identifiants
pubmed: 32081452
pii: S0213-005X(20)30014-8
doi: 10.1016/j.eimc.2019.12.018
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Tigecycline
70JE2N95KR
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
471-473Informations de copyright
Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.